Eli Lilly (LLY)

1,078.78
+14.63 (1.37%)
NYSE· Last Trade: Jun 3rd, 4:29 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1,064.15
Open1,059.50
Bid1,078.48
Ask1,084.91
Day's Range1,053.51 - 1,093.28
52 Week Range623.78 - 1,149.10
Volume2,579,220
Market Cap1.03T
PE Ratio (TTM)47.01
EPS (TTM)22.9
Dividend & Yield6.920 (0.64%)
1 Month Average Volume3,194,999

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

Forget Zepbound: Eli Lilly's Next Billion-Dollar Weight-Loss Drug May Be Even Betterfool.com
Can any company pose a serious challenge to Eli Lilly in the weight-loss market?
Via The Motley Fool · June 3, 2026
Here's What I Think Is Really Going on With Novo Nordisk Stockfool.com
There is light at the end of the tunnel.
Via The Motley Fool · June 3, 2026
Prediction: Eli Lilly Will Be Worth More Than SpaceX in 2 Yearsfool.com
SpaceX looks like a rocket, but don't fly too close to the sun. Here's why Eli Lilly is likely a better stock to own.
Via The Motley Fool · June 3, 2026
Eli Lilly & Co. (NYSE:LLY) Ranks as a Textbook Growth Stockchartmill.com
Via Chartmill · June 1, 2026
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn'tfool.com
This particular sector may suit cautious and aggressive investors.
Via The Motley Fool · June 3, 2026
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · June 3, 2026
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease Innovation
Recent Industry Activity Reinforces the Need for Manufacturing Resilience, Diversified Vaccine Supply, and Health Security Amid an Evolving Global Biothreat Landscape
Via TheNewswire.com · June 3, 2026
Bull vs. Bear: The Quick Take on Viking Therapeutics Stockfool.com
The pharmaceutical company's most promising drug candidate has some potential advantages over its rivals.
Via The Motley Fool · June 3, 2026
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Year, According to Wall Streetfool.com
Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year.
Via The Motley Fool · June 3, 2026
Eli Lilly Just Proved Gene Editing Could Be Pharma's Next Gold Rush -- but CRISPR Therapeutics Investors Should Watch Outfool.com
Eli Lilly's pipeline is an embarrassment of riches.
Via The Motley Fool · June 3, 2026
Meet the Biotech Stock That's Trouncing Lilly, Merck, and Pfizer in 2026fool.com
It is finally bouncing back after several challenging years.
Via The Motley Fool · June 3, 2026
Vanguard (VHT) Vs. Simplify (PINK): Which Healthcare ETF Is the Better Buy for Investors?fool.com
Explore how two healthcare ETFs stack up in cost, yield, and strategy, with one fund emphasizing innovation and charitable impact.
Via The Motley Fool · June 2, 2026
Nvidia's Jensen Huang Just Gave Marvell Technology a Huge Boostfool.com
Huang has lofty expectations for Marvell Technology.
Via The Motley Fool · June 2, 2026
Eli Lilly Wins Back CVS Health, Reverting Novo's Advantagemarketbeat.com
Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.
Via MarketBeat · June 2, 2026
Viking Therapeutics' Q3 Catalyst That Could Turn Eli Lilly's and Novo Nordisk's Daily Weight Loss Pill Strategy Upside Downfool.com
An upcoming trial result could change how investors think about the weight-loss drug market.
Via The Motley Fool · June 2, 2026
Adding a Healthcare Stock to Your Portfolio? FHLC Offers Broad Coverage While PPH Leads in Returns.fool.com
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story.
Via The Motley Fool · June 2, 2026
State Street's Health Care ETF Tops Invesco's on Yield and Returnsfool.com
Expense ratios, dividend yields, and risk profiles set these healthcare ETFs apart. See how their strategies shape long-term performance for investors.
Via The Motley Fool · June 2, 2026
U.S. Health Care Depth or Global Industry Reach? VHT vs. IXJfool.com
The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S. exposure, while the other adds global reach in a sector shaped by drug pricing, patent cycles, regulation, and medical innovation.
Via The Motley Fool · June 1, 2026
Trump Said 'Micron's Great'—And Now Micron's Worth More Than Walmart, Eli Lilly, Berkshire Hathawaybenzinga.com
Micron Technology just became the 12th-biggest company in the world, bigger than Berkshire Hathaway. UBS sees another 56% upside as June 24 earnings near.
Via Benzinga · June 1, 2026
These 8 Words From Eli Lilly's CEO Have Wall Street Turning Bullishfool.com
David Ricks was addressing the pharmaceutical titan's latest hot product.
Via The Motley Fool · June 1, 2026
Eli Lilly Deepens Innovation Push Through New Biopharma Collaborationsbenzinga.com
Eli Lilly signs drug development deals with Hanmi and Haisco as Retevmo Phase 3 data show an 83% cut in recurrence risk.
Via Benzinga · June 1, 2026
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Via Chartmill · June 1, 2026
Is Eli Lilly Starting an Nvidia-Style Run?fool.com
Lilly shares soared more than 18% in May.
Via The Motley Fool · June 1, 2026
3 of Wall Street’s Favorite Stocks We Think Twice About
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via StockStory · June 1, 2026
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...
Via StockStory · May 31, 2026